For the population science project, we assembled an interdisciplinary team, co-led by applied (epidemiologist) and basic (telomere biologist) scientists, to verify a novel tissue biomarker for prostate cancer prognosis that we discovered - telomere length variability in prostate cancer cells combined with short telomere length in cancer-associated stromal cells ("telomere biomarker"). In our prospective cohort study, men with this combination had 14-times the risk of prostate cancer death;men without this combination rarely died of their cancer over 15 years. Due to the fact that current prognostic factors inadequately distinguish between aggressive and nonaggressive disease, new prognostic biomarkers that inform beyond the currently used clinico-pathologic factors are needed to enhance treatment and surveillance decision-making. We will address this important unmet clinical need for improved risk stratification for prostate cancer patients. While our prior findings point to the clinical utility of the telomere biomarker, we have completed only the discovery phase. Here, we propose to;1) Demonstrate the validity and reproducibility of an automated "TELl-FISH" method, our FISH-based telomere length measurement tool, using the same prospective cohort study in which we made our discovery. A valid and reproducible high-throughput method for measuring the biomarker is needed for the proposed epidemiologic study on prognosis, and in future epidemiologic studies on eariy detection and active surveillance. 2) Conduct a nested case-control study to verify the association between the telomere biomarker, assessed using automated TELl-FISH, and risk of lethal prostate cancer. 3) Determine optimal outpoints to refine the telomere biomarker for prognosis using both cohorts. 4) Evaluate whether prevalence of the refined telomere biomarker differs across age, race, and other patient characteristics. Differences in biomarker prevalence may inform the racial disparity in disease aggressiveness. We will extensively use the Pathology, Biostatistics, and Administrative Gores. We expect the telomere biomarker will be translated for clinical prognostic utility for prostate cancer in a trial in 5 years.

Public Health Relevance

We expect that the telomere biomarker may identify prostate cancer patients who require enhanced treatment and surveillance, and importantly, patients who may not need intensive additional treatment, and possibly may not require treatment at all. Improved risk stratification allowing for individualized clinical management has the potential to increase the benefit to risk, and reduce healthcare costs for prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058236-19A1
Application #
8739715
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
1997-09-30
Project End
2019-08-31
Budget Start
2014-09-25
Budget End
2015-08-31
Support Year
19
Fiscal Year
2014
Total Cost
$186,558
Indirect Cost
$71,399
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Guedes, Liana B; Morais, Carlos L; Almutairi, Fawaz et al. (2016) Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res 22:4651-63
Haffner, Michael C; Weier, Christopher; Xu, Meng Meng et al. (2016) Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol 238:31-41
Barakat, David J; Mendonca, Janet; Barberi, Theresa et al. (2016) C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Cancer Lett 375:152-61
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9
Jackson, Christopher M; Kochel, Christina M; Nirschl, Christopher J et al. (2016) Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res 22:1161-72
Hedayati, Mohammad; Haffner, Michael C; Coulter, Jonathan B et al. (2016) Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clin Cancer Res 22:3310-9
Trock, Bruce J; Fedor, Helen; Gurel, Bora et al. (2016) PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Mod Pathol 29:764-71
Wu, Jianguo; Ivanov, Andrei I; Fisher, Paul B et al. (2016) Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling. Elife 5:
Levy, Oren; Brennen, W Nathaniel; Han, Edward et al. (2016) A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials 91:140-50
Lotan, Tamara L; Wei, Wei; Morais, Carlos L et al. (2016) PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus 2:180-188

Showing the most recent 10 out of 691 publications